$CTOR
Citius Oncology, Inc. Common Stock
XNAS
Why is CTOR down today? It is at $0.775 (-1.27%), and our scanner flagged it 1 time on unusual volume this month. See the catalyst behind the move, real-time alerts the moment CTOR spikes, and full due diligence on CTOR — key stats, earnings, dilution and insider activity. Free.
Get free $CTOR alerts the moment volume spikes
Our scanner flagged $CTOR 1 time in the last 30 days. Create a free account to track $CTOR, build a watchlist, and get instant unusual-volume alerts — plus 5 free premium days, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $0.775
- Change today
- -1.27%
- Previous close
- $0.785
- 52-week range
- $0.491 – $2.25
- Market cap
- $73M
- Institutional own.
- 15.97%
- Total held
- 22.4%
- Tradeable float
- 72.2M 78% of shares · after 6% insiders + 16% institutions
- Short interest
- 365K ▼ -19% vs prior · as of 2026-07-15
- Short % of float
- 0.5%
- Days to cover
- 8.3d
- Avg daily volume
- 254K
- Next earnings
- Aug 11 · in 5d
- Exchange
- XNAS
- 5mthin
- 1.1x
- 15mthin
- 0.7x
- 1hthin
- 1.4x
- 1D
- 0.9x
Get free CTOR + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $CTOR down today?
Here is the latest on CTOR from our scanner (live price and day move above). Fresh from the SEC: Citius Oncology Reports Strong Commercial Momentum. A material company disclosure like this is often the real catalyst behind a move of this size.
Likely catalystCitius Oncology Reports Strong Commercial MomentumReported increased 78% quarter over quarterReported for LYMPHIR currently exceeds $400 millionReported quarter ended June 30, 2026, the number of new institutions increased 78% compared with the prior quarter. Vials ordered by institutions, from the latest SEC filing. Read it →Analyst data via Nasdaq. Not investment advice.
Insiders
0 buys, 0 sells last 3 months (11/0 over 12 months)Show 12 recent transactionsMinimize 12 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Dutia Suren G Director | Acquired (grant/award) | +300K 0.3% of company | n/a | 300K | n/a | Sep 19, 25 |
Mcgrath Dennis M Director | Acquired (grant/award) | +300K 0.3% of company | n/a | 300K | n/a | Sep 19, 25 |
Holuka Eugene Myron Director | Acquired (grant/award) | +300K 0.3% of company | n/a | 300K | n/a | Sep 19, 25 |
Bartushak Jaime Officer | Acquired (grant/award) | +825K 0.9% of company | n/a | 825K | n/a | Sep 19, 25 |
Mayersohn Joel David Director | Acquired (grant/award) | +300K 0.3% of company | added 100% | 321K | n/a | Sep 19, 25 |
Webb Carol Director | Acquired (grant/award) | +300K 0.3% of company | n/a | 300K | n/a | Sep 19, 25 |
Holubiak Myron Z Officer | Acquired (grant/award) | +850K 0.9% of company | n/a | 850K | n/a | Sep 19, 25 |
Holubiak Myron Z Officer | Acquired (grant/award) | +100K 0.1% of company | n/a | 100K | n/a | Sep 19, 25 |
Smith Robert Joseph Director | Acquired (grant/award) | +300K 0.3% of company | n/a | 300K | n/a | Sep 19, 25 |
Mazur Leonard L Officer | Acquired (grant/award) | +1.70M 1.8% of company | n/a | 1.70M | n/a | Sep 19, 25 |
Czuczman Myron Officer | Acquired (grant/award) | +825K 0.9% of company | n/a | 825K | n/a | Sep 19, 25 |
Mayersohn Joel David Director | Acquired (grant/award) | +21K 0.02% of company | n/a | 21K | n/a | Jul 28, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Active shelfRecent share offering + active shelf on file — the company raised capital and can raise more. If $CTOR runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$CTOR Sentiment
BullishBlend of news sentiment, today’s move, and community votes. Not investment advice.
$CTOR Activity
News, unusual-volume alerts, AI-trader trades and community chatter — the whole story, newest first.
CTOR stock FAQ
Why is $CTOR down today?
Here is the latest on CTOR from our scanner (live price and day move above). Fresh from the SEC: Citius Oncology Reports Strong Commercial Momentum. A material company disclosure like this is often the real catalyst behind a move of this size.
What is the CTOR stock price today?
CTOR last traded at $0.775, down 1.27% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
When does CTOR report earnings?
Citius Oncology, Inc. Common Stock (CTOR) is next expected to report earnings on Tuesday, August 11, 2026, about 5 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
Where can I see live CTOR alerts?
The CTOR Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged CTOR 1 time in the last 30 days.
What exchange is CTOR on?
CTOR (Citius Oncology, Inc. Common Stock) trades on XNAS, with a market cap of about $73M.
Is CTOR good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge CTOR for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.